Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Sara ElAdawy
- Target Recruit Count
- 80
- Registration Number
- NCT05847244
- Locations
- 🇪🇬
Cairo University Hospitala, Cairo, Egypt
🇪🇬Cairo University Hospitals, Cairo, Egypt
Polypill Versus Metformin in New Onset Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- George Medicines PTY Limited
- Target Recruit Count
- 334
- Registration Number
- NCT05833958
A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Turning Point Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05828303
- Locations
- 🇪🇸
Local Institution - 2138, Madrid, M, Spain
🇺🇸Local Institution - 2102, Denver, Colorado, United States
🇺🇸Gabrail Cancer Center Research, Canton, Ohio, United States
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05815680
- Locations
- 🇨🇳
Aerospace Center Hospital, Beijing, Beijing, China
Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT05781711
- Locations
- 🇪🇬
Faculty of Medicine, Menoufia University, Tanta, Shebeen El-Kom, Egypt
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2023-05-16
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05779644
- Locations
- 🇨🇳
Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
The Effects of Acetyl-L-Carnitine and Myo/Chiro-Inositol in Patients With PCOS
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Khyber Medical University Peshawar
- Target Recruit Count
- 120
- Registration Number
- NCT05767515
- Locations
- 🇵🇰
Khyber Medical University, Peshawar, Pakistan
A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05768360
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT05759312
Safety and Efficacy of DIDALA Monotherapy in Patients With Type 2 Diabetes Compared With Metformin.
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2023-03-08
- Target Recruit Count
- 140
- Registration Number
- NCT05760456
- Locations
- 🇻🇳
National Hospital of Traditional Medicine, Hanoi, Vietnam
🇻🇳Hanoi Hospital of Traditional Medical, Hanoi, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.